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Abstract
Background: Human embryonic stem (hES) cells hold considerable promise for cell replacement
and gene therapies. Their remarkable properties of pluripotency, self-renewal, and tractability for
genetic modification potentially allows for the production of sizeable quantities of therapeutic cells
of the hematopoietic lineage. Dendritic cells (DC) arise from CD34+ hematopoietic progenitor
cells (HPCs) and are important in many innate and adaptive immune functions. With respect to
HIV-1 infection, DCs play an important role in the efficient capture and transfer of the virus to
susceptible cells. With an aim of generating DCs from a renewable source for HIV-1 studies, here
we evaluated the capacity of hES cell derived CD34+ cells to give rise to DCs which can support
HIV-1 infection.
Results: Undifferentiated hES cells were cultured on S17 mouse bone marrow stromal cell layers
to derive CD34+ HPCs which were subsequently grown in specific cytokine differentiation media
to promote the development of DCs. The hES derived DCs (hES-DC) were subjected to
phenotypic and functional analyses and compared with DCs derived from fetal liver CD34+ HPC
(FL-DC). The mature hES-DCs displayed typical DC morphology consisting of veiled stellate cells.
The hES-DCs also displayed characteristic phenotypic surface markers CD1a, HLA-DR, B7.1, B7.2,
and DC-SIGN. The hES-DCs were found to be capable of antigen uptake and stimulating naïve
allogeneic CD4+ T cells in a mixed leukocyte reaction assay. Furthermore, the hES-DCs supported
productive HIV-1 viral infection akin to standard DCs.
Conclusion: Phenotypically normal and functionally competent DCs that support HIV-1 infection
can be derived from hES cells. hES-DCs can now be exploited in applied immunology and HIV-1
infection studies. Using gene therapy approaches, it is now possible to generate HIV-1 resistant
DCs from anti-HIV gene transduced hES-CD34+ hematopoietic progenitor cells.
Background
Human embryonic stem (hES) cells are endowed with
pluripotential and self-renewal properties [1,1]. In addi-
tion, they are tractable for stable genetic modification.
These attributes qualify them as potential candidates to
derive an unlimited supply of any cell type for transplan-
tation, gene therapy, drug screening and functional
genomic applications. A number of previous studies have
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demonstrated the ability of hES cells to differentiate into
a myriad of cell types that include neurons, hematopoietic
cells, cardiomyocytes, and insulin-secreting cells, to name
a few [3-9]. Many new studies are currently directed
towards expanding the use of hES cells for novel applica-
tions.
In this regard, the ability to generate cells of the hemat-
opoietic system has considerable potential in several areas
of clinical and experimental medicine as they can recon-
stitute the entire blood system and can serve as primary
targets in gene therapy in treating infectious diseases such
as AIDS and inherited diseases [9,10]. Given the present
lack of effective vaccines and the ineffectiveness of drug
based therapies for a complete cure with regard to HIV/
AIDS, new and innovative approaches are essential
[10,11]. Gene therapy through intracellular immuniza-
tion offers a promising alternative approach and possible
supplement to current HAART therapy. A primary goal of
many ongoing studies is to introduce an effective anti-HIV
gene into hematopoietic progenitor cells [11]. As these
cells possess the ability to self-renew, they have the poten-
tial to continually produce HIV resistant T cells, macro-
phages, and dendritic cells in the body thus providing
long term immune reconstitution. These approaches use
CD34+ hematopoietic stem cells for anti-HIV gene trans-
duction via integrating viral vectors such as lentiviral vec-
tors. Current sources of CD34+ cells are restricted to
human umbilical cord blood (CB), adult bone marrow
(BM), mobilized peripheral blood, (MPB), and fetal liver
[11]. hES cells are a good viable alternative for the gener-
ation of an unlimited supply of CD34+ cells thus paving
the way for utilization of these cells for hematopoietic cell
therapy [9]. Recently we demonstrated derivation of phe-
notypically and functionally normal macrophages from
hES-CD34+ cells and established that they could support
HIV-1 infection. These studies laid the ground work for
utilizing hES-CD34+ cells in HIV research and for testing
anti-HIV genes in a gene/cell therapy setting [10].
Similar to monocytes/macrophages, dendritic cells (DCs)
also originate from hematopoietic progenitor cells and
spread via the bloodstream and lymphatics [12,13]. They
are found in almost every organ as sentinels of the
immune system. In innate immunity, DCs function via
type-1 interferon activation of both macrophges and NK
cells. In adaptive immunity, DCs constitute the most pow-
erful antigen presenting cells (APCs) that prime naïve T
lymphocytes and sensitize cytotoxic T lymphocytes to the
antigens they present [13]. Thus, efficient generation of
these cells from renewable sources such as hES cells would
have great potential for immunotherapy applications.
However in HIV-1 infection, in addition to being infected
and functionally compromised, paradoxically they are
also culprits in the efficient transfer of the virus to suscep-
tible cells [14]. Thus in gene therapy applications for HIV
infections they are also among principal cells that need to
be protected. For such efforts to proceed further, it is
important to evaluate if hES derived DCs are functionally
normal and support HIV-1 infection. As a first step
towards this goal, here we show that hES-CD34+ cells can
give rise to normal DCs which are capable of supporting
HIV-1 infection.
Results
Hematopoietic differentiation of human ES cells and 
derivation of dendritic cells
hES cell line H1 was propagated as undifferentiated cells
by co-culture on mitomycin treated MEF feeder layers.
Consistent with previous studies, cells cultured in this
manner grew as tightly packed colonies (Figure 1A). To
promote hematopoietic differentiation, the H1 cell colo-
nies were cocultured with irradiated S17 cells [10]. After
4–7 days in culture, the H1 cells differentiated into cystic
bodies (Figure 1B) which were allowed to further expand
for 14–17 days. FACS analysis of single cell suspensions of
the differentiated cells showed the development of
CD34+ cells (range 7% to 15%, data not shown). Purified
CD34+ cells were later cultured in dendritic cell differen-
tiation media in parallel with CD34+ cells from fetal liver.
Cell morphology and phenotypic properties were moni-
tored periodically. By day 12, the differentiating cells
showed a characteristic veiled or dendritic appearance
with numerous cytoplasmic extensions indicative of DC
development (Figure 1C). FL-DCs and hES-DCs were
found to be morphologically similar as seen in the phase-
contrast images (Fig 1C and 1D). We also looked for the
expression markers during differentiation and figure 2
illustrates CD1a and CD14 expression at days 0, 3, and
12. At day 0, CD34+ cells expressed neither CD1a nor
CD14. By day 3, two cell populations expressing either
CD1a or CD14 could be seen with the CD14 single posi-
tive population being the majority. With hES CD34+ cells,
by day 12, 34% of the cells differentiated into CD1a
expressing DCs. The overall yield of CD1a+ cells prepared
in this manner ranged from 8–34% for hESC-DCs and
20–64% for FL-DCs.
hES derived DCs (hES-DC) express normal DC surface 
markers
The mature DCs were generated from hES cells by cultur-
ing for 12 days in media containing the growth factors
and cytokines as mentioned above. Following differentia-
tion, hES-DCs were analyzed for expression of the human
class II antigen presenting molecule HLA-DR and the co-
stimulatory molecules B7.1 (CD80) and B7.2 (CD86) by
FACS. The antigen presenting cell surface marker HLA-DR
present on mature DCs is critical for presenting antigen to
T cells and the co-stimulatory molecules B7.1 and B7.2
activate T cells [13-17]. For a two color FACS analysis, cellsAIDS Research and Therapy 2008, 5:1 http://www.aidsrestherapy.com/content/5/1/1
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were stained with CD1a and HLA-DR, CD1a and B7.1,
and CD1a and B7.2. Results showed that hES derived DCs
are positive for HLA-DR, B7.1, and B7.2 surface expres-
sion (Figure 3). The expression levels are comparable
between hES-DCs and FL-DCs: CD1a+HLA-DR+ (10.5%
and 9.6%), CD1a+B7.1+  (14% and 15.4%), and
CD1a+B7.2+ (11.4% and 12.9%) cells. We also observed
single positive cell populations for CD1a, HLA-DR, B7.1,
and B7.2 which most likely represent other subsets of
DCs. These above data indicate that phenotypically nor-
mal DCs can be generated from hES-CD34+ cells.
hES-DC express Dendritic Cell-specific ICAM-3-grabbing 
nonintegrin (DC-SIGN)
DC-SIGN (CD209) is a DC-specific C-type lectin which is
expressed by mature DCs. DC-SIGN plays a vital role in
establishing the initial contact between DCs and resting T
cells through its recognition of ICAM-3 receptor [13-15].
In addition, with regard to HIV infection, it was found
that DC-SIGN bound virus is more stable and is more effi-
ciently transferred to susceptible target cells [13,14]. We
therefore examined the hES-DCs for its presence by stain-
ing with anti-DC-SIGN-PE and anti-CD1a-PECY5 conju-
gated antibodies. Results showed that a significant
percentage of hES-DC (14.4%) express DC-SIGN similar
to FL-DCs (14.3%) (Figure 3). We also observed cell pop-
ulations single positive for CD1a and DC-SIGN which
could represent other DC subtypes.
hES-DCs are capable of allogeneic T cell stimulation
Since DCs are capable of potent stimulation and prolifer-
ation of allogeneic T cells, we sought to determine
whether the hES-DCs were also able to elicit such a
response in a mixed leukocyte reaction (MLR). The day 12
differentiated hES-DCs and FL-DCs, immuno-magneti-
cally sorted based on CD1a+ were used, and proliferation
was measured by BrdU uptake using FACS after staining
with PE-conjugated anti-BrdU antibody as described in
Methods. Results showed that hES-DCs mediated a signif-
icant stimulation of allogeneic T cells similar to FL-DCs
(Figure 4). The ratio of DCs to the T cells in the reaction
mix is expressed as 1:125, 1:250, 1:500, 1:1000, 1:2000
and 1:4000. Highest stimulation was seen with the lower
DC to T cell ratio (1:125) and the levels of stimulation
decreased at higher ratios. The percent stimulation of T-
cells by hES-DCs and FL-DCs were similar at the ratios
1:500 to 1:4000. These results demonstrated the capacity
of hES-DCs for allogeneic T cell stimulation.
hES-DCs are capable of antigen uptake
An essential function of the DCs is their ability to capture
and present antigen to T-cells. The capacity of DCs to take
up antigens was measured by using Alexa-dextran, as an
indicator of mannose-receptor (MR)-mediated endocyto-
sis. The level of antigen uptake by DCs was expressed as
the difference in percentages between the test samples
incubated at 37°C versus the controls at 0°C. Results
showed that hES-DCs are capable of antigen uptake. How-
ever, the levels of uptake were found to be about one fold
less than that of FL-DCs (27.5% versus 61.0%) (Figure 5).
This could be due to differences in cell types of origin and/
or due to their physiological condition at the time of har-
vest. These results further support the notion that the hES-
DCs are functionally competent in addition to being mor-
phologically and phenotypically normal.
hES-DCs can support productive HIV-1 infection
The above results have collectively shown that hES-DCs
are similar to normal DCs as demonstrated by compara-
tive analysis with FL-DCs. Apart from being critical for
host immunity, DCs can be infected and disabled by
viruses such as HIV-1 [13,14]. As mentioned above, DCs
also play an important role in the natural history of HIV
infection. At the early phase of HIV-1 transmission, DCs
capture HIV-1 at mucosal surfaces and transmit the virus
to T-cells in the vicinity. Capture of the virus on DCs is
known to take place via C-type lectin DC-SIGN surface
molecule. Therefore, we wanted to determine if hES-DCs
were susceptible to HIV-1 infection as compared to nor-
mal DCs. Accordingly, the CD1a-sorted hES-DCs and FL-
DCs were exposed to HIV-GFP, a T-tropic virus containing
Derivation of DCs from hES cells Figure 1
Derivation of DCs from hES cells: Undifferentiated hES 
cells were cocultured with S17 mouse stromal cells to derive 
cystic bodies. Later, purified CD34+ cells derived from cystic 
bodies and fetal liver were cultured in cytokine media to 
derive DCs as described in Methods. A and B, representative 
hES colony and an cystic body respectively. C and D, mor-
phology of DCs differentiated from hES and FL derived 
CD34+ cells.AIDS Research and Therapy 2008, 5:1 http://www.aidsrestherapy.com/content/5/1/1
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FACS analysis of differentiating DCs from hES and FL CD34+ cells Figure 2
FACS analysis of differentiating DCs from hES and FL CD34+ cells: CD34+ cells were cultured in cytokine media and 
analyzed by FACS for CD14 and CD1a markers at different days by staining with CD1a-PECY5 and CD14-PE conjugated anti-
bodies. Dot plots are representative of triplicate experiments.
Phenotypic analysis of hES-DCs and FL-DCs Figure 3
Phenotypic analysis of hES-DCs and FL-DCs: hES-DCs and FL-DCs were stained with antibodies CD1a-PECY5, HLA-
DR-PE, B7.1-PE, B7.2-PE, and DC-SIGN-PE. Expression of these respective markers was analyzed by FACS. Percent positive 
cells are indicated in respective plots for each of the cell surface markers. The isotype controls are shown in the left panel. 
Data is representative of triplicate experiments.AIDS Research and Therapy 2008, 5:1 http://www.aidsrestherapy.com/content/5/1/1
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the gene for green fluorescent protein (GFP). Our results
showed that both of the virus-exposed hES-DCs and FL-
DCs supported viral infection based on GFP expression by
the respective cells. However, not all the cells in the cul-
ture were productively infected as only a fraction of cells
were virus positive for GFP expression. (Figure 6). Super-
natants from infected DC cultures were also positive of
p24 viral antigen indicative of productive infection. The
levels of virus production were not copious however,
which is not unexpected since DCs are known to support
only a low level viral replication [13,18].
Discussion
Towards the goal of exploiting hES cells for novel hemat-
opoietic cell reconstitution and HIV gene therapies, here
we have shown that phenotypically normal and function-
ally competent dendritic cells could be differentiated from
hES-CD34+ cells. Moreover, we also have demonstrated
for the first time that hES-DCs can be productively
infected with HIV-1 thus allowing future testing of anti-
HIV therapeutic genes such as siRNAs for efficacy in these
cells.
In these studies, we induced hES derived CD34+ cells to
differentiate into myeloid DCs in the presence of
cytokines SCF, GM-CSF, Flt3, IL-3, TNF-α, and IL-4.
CD34+ cells derived from human fetal liver were also
evaluated in parallel for comparison. Based on FACS anal-
ysis for surface markers during culture, CD34+ cells differ-
entiated into mature myeloid DCs showing the typical
CD1a phenotype similar to those derived from FL CD34+
cells. The morphology and phenotypic characteristics of
hES-DCs were found to be similar to that of DCs derived
from fetal liver CD34+ cells cultured in parallel.
It is important that hES-DCs are also functionally normal
for future applications. Therefore we analyzed the func-
tional markers HLA-DR (MHC-II), B7.1 (CD80), and B7.2
(CD86) typically expressed by mature DCs. The antigen
presenting cell surface marker, HLA-DR present on mature
DCs is critical for antigen presentation to CD4+ T cells and
the co-stimulatory molecules B7.1 and B7.2 are needed to
activate T cells. The mature hES-DCs expressed HLA-DR,
B7.1, and B7.2 surface molecules which were comparable
with levels expressed in FL-DCs. Consistent with the DCs'
ability, the hES-DCs also showed normal capacity for anti-
gen capture as evidenced by dextran uptake. We further
analyzed the capacity of hES-DCs to induce proliferation
of allogeneic T cells in a mixed leukocyte reaction. Our
results showed that hES-DCs indeed are capable of medi-
ating this allogeneic response. We also evaluated the
expression of another cell surface molecule, DC-SIGN
(CD209) which is a DC-specific adhesion receptor
belonging to the C-type lectin family involved in the inter-
actions with T cells [13,14]. Our results showed similar
levels of DC-SIGN in hES-DCs and FL-DCs. The above
data taken together showed that hES-DCs are phenotypi-
cally and functionally normal.
It is known that HIV-1 can infect DCs with the virus
remaining stable for long periods. DCs transmit the virus
efficiently to CD4 T cells and therefore play an important
role in HIV-1 infection. Our results showed that hES-DCs
were susceptible to HIV-1 infection similar to that of FL-
DCs. However, not all the cells in the culture were produc-
tively infected and the levels of viral production are low.
This is consistent with previous findings that DCs support
only a low level replication and fully mature DCs may
have a block in viral replication [13,14]. A recent report
has also demonstrated the derivation of physiologically
normal DCs from hES-CD34+ cells using a different pro-
tocol and compared these to those derived from adult
human CD34+ cells and peripheral blood monocytes
[19]. Our results are in agreement and confirmed these
previous findings, and additionally extended them further
by demonstrating that hES-DCs are also susceptible to
HIV-1 infection.
Allogeneic T-cell stimulation by hES and FL derived DCs Figure 4
Allogeneic T-cell stimulation by hES and FL derived 
DCs: The allogeneic stimulatory properties of DCs were 
assessed in a mixed leukocyte reaction assay using allogeneic 
T-cells. Graded numbers of sorted and irradiated DCs were 
co-cultured with 5 × 105 allogeneic T cells. BrdU incorpora-
tion was determined by FACS using a PE-conjugated antibody 
against BrdU. Histograms depict relative percent of BrdU 
uptake when compared to positive control cells stimulated 
with IL-2 and PHA. The X-axis is expressed as ratio of stimu-
lator DCs cells to allogeneic responder T cells.AIDS Research and Therapy 2008, 5:1 http://www.aidsrestherapy.com/content/5/1/1
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In HIV-1 disease, infection of CD4 T cells leads to their
eventual decline whereas infection of monocytes/macro-
phages and dendritic cells leads to continued viral spread
and defects in antigenic presentation thus exacerbating
the disease process [14]. We previously demonstrated the
derivation of macrophagres from hES-CD34+ cells
whereas studies of Galic et al [20] derived functional T
cells from hES-CD34+ cells in vivo using humanized
mice. Whether the hES derived T cells support HIV-1
infection remains to be determined. Lentiviral vector
transduction of hES cells and derivation of functional
macrophages and T cells that retained the expression of
the transgene established that hES cells are tractable for
deriving gene modified end-stage primary hematopoietic
cells [10,20]. Moreover, our present results together with
our previous findings that both hES derived DCs and mac-
rophages are susceptible to HIV infection paved the way
for testing anti-HIV constructs introduced into either hES
cells or their derivative hematopoietic progenitor CD34+
cells. Thus far many previous studies including our own
evaluated a variety of anti-HIV gene constructs in a hemat-
opoietic stem cell setting using CD34+ cells from routine
sources such as bone marrow and cord blood [11]. Newer
and more potent novel constructs such as siRNAs are cur-
rently being investigated some of which are currently
entering clinical trials [21]. In addition to anti-HIV genes
with a direct inhibitory action on viral molecules, siRNAs
and ribozymes that down regulate cellular molecules that
aid in HIV-1 infection such as viral coreceptors CCR5 and
CXCR4 also show considerable promise [22,23]. Such
constructs can now be introduced into hES cells and their
Antigen uptake by hES-DCs Figure 5
Antigen uptake by hES-DCs: Cultured hES and FL DCs were sorted based on CD1a marker. The cells were then incubated 
with Alexa-Dextran at 0°C and 37°C for 1 hr and analyzed by FACS as described in Methods. The percent antigen uptake was 
measured as the difference in percentages between the test (37°C) and control (0°C). The percent positive cells are indicated 
in the plots for both hES-DCs and FL-DCs. Data are representative of triplicate experiments.AIDS Research and Therapy 2008, 5:1 http://www.aidsrestherapy.com/content/5/1/1
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efficacy tested in end-stage cells represented by DCs, mac-
rophages, and T cells.
In summary, our data demonstrated the development of
terminally differentiated DCs derived from hES cells. The
hES-DCs display typical DC morphology, express normal
phenotypical markers, are capable of antigenic stimula-
tion, and support HIV-1 infection.
Conclusion
Phenotypically normal and functionally competent den-
dritic cells could be derived from hES-CD34+ cells. Large
numbers of these hES-DCs cells can now be cultured from
a renewable source for use in cell and immune-based ther-
apies. Since these cells also support productive HIV-1
infection, they provide a uniform source of DCs for viral
infection studies. It is also now feasible to gene transduce
either hES cells themselves and/or hES derived CD34+
cells with anti-HIV genes such as inhibitory siRNAs and
test their antiviral efficacy in down stream differentiated
DCs which are among the primary target cells that need to
be protected against HIV-1 infection.
Methods
hES cell growth and propagation
H1 human embryonic stem cell line (hES) was obtained
from WiCell (Madison, Wisconsin). The undifferentiated
cells were maintained by co-culture with mitomycin C
treated mouse embryonic fibroblast (MEF) cells (Chemi-
con, Temecula, CA) in DMEM/F12 medium supple-
mented with 20% knockout serum replacer (Invitrogen),
1% MEM-non essential amino acids (Invitrogen), 1 mM
L-glutamine, 0.1 mM β-mercaptoethanol (Invitrogen),
0.5% penicillin/streptomycin and 4 ng/ml human basic
fibroblast growth factor (Invitrogen). Culture media was
replaced daily with fresh complete medium. Mature colo-
nies were subculture weekly by digesting with collagenase
IV (Invitrogen) as previously described [10].
Differentiation of hES cells into DCs
The undifferentiated hES cells (H1) were harvested by
treatment with 1 mg/ml collagenase IV (Invitrogen) and
dispersed by scraping to maintain the cells in small
clumps. The hES cells were added to irradiated (35 Gy)
S17 mouse bone marrow derived cell layers and cultured
with differentiation media composed of RPMI supple-
mented with 15% FBS (HyClone), 2 mM L-glutamine, 0.1
mM  β-mercaptoethanol, and 1% MEM-nonessential
amino acids, 1% penicillin/streptomycin. Media was
changed every 2 to 3 days. After indicated days (14–17
days), the differentiated hES cystic bodies were harvested
and digested into single cell suspension using collagenase
type IV followed by 0.05% trypsin/EDTA supplemented
with 2% chick serum (Invitrogen) for 20 minutes at 37°C.
Cells were washed twice with phosphate-buffered saline
(PBS), filtered through a 70-µM cell strainer (BD Bio-
sciences). To assess the levels of CD34+ hematopoietic
progenitor cells in the bulk cell suspension, cells were
labeled with PE conjugated anti-CD34+ antibody (BD
Biosciences, San Jose, CA) and analyzed by FACS. To
purify the CD34+ cells, Direct CD34+ Progenitor Cell Iso-
lation Kit (Miltenyi Biotech, Auburn, CA) was used as rec-
ommended by the manufacturer's protocol. Isolated
CD34+ cell purity was determined by FACS like above. For
comparative experiments, human CD34+ cells were also
purified from fetal liver tissue as described above [24]. To
derive DCs, the purified CD34+ cells (~4 × 105 to 6 × 105
cells) were cultured in Iscove's media containing 10 ng/ml
HIV-1 infection of hES and FL DCs Figure 6
HIV-1 infection of hES and FL DCs: To determine virus susceptibility, FL and hES DCs were infected with a replication 
competent X4-tropic HIV-GFP reporter virus strain at an m.o.i. of 0.2. At 6 days post infection, cells were visualized by fluores-
cence microscopy to determine GFP expression in productively infected cells at the single cell level. Phase contrast and fluo-
rescence images are shown for the respective cell types (A). Infected culture supernatants were assayed for viral p24 antigen 
by ELISA at different days post-infection (B). Data is representative of duplicate experiments.AIDS Research and Therapy 2008, 5:1 http://www.aidsrestherapy.com/content/5/1/1
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each of SCF, IL-3, TNF-α, IL-4 and 50 ng/ml each of GM-
CSF and Flt-3. The differentiated mature dendritic cells
were used for subsequent phenotypic and functional anal-
ysis.
Phenotypic analysis of hES-DCs
To determine if hES derived DCs were phenotypically nor-
mal, analysis of the characteristic cell surface markers was
performed by FACS using respective conjugated antibod-
ies against CD1a-PECY5, CD14-PE, HLA-DR-PE, B7.1-PE,
B7.2-PE and DC-SIGN-PE. Fetal liver CD34+ cell derived
DCs were also evaluated in parallel. Blocking step was first
performed by incubating the cells with the respective iso-
type sera control for 30 minutes at 4°C before staining
with the respective cell surface marker antibodies. Isotype
control staining was used to determine background levels.
FACS analysis was performed on Beckman-Coulter
EPICS®XL-MCL flow cytometer with data analysis using
EXPO 32 ADC software (Coulter Corporation, Miami,
FL). A minimum of 10,000 cells were analyzed in each
FACS evaluation.
Functional analysis of hES-DCs by Mixed Leukocyte 
Reaction (MLR) assay and antigen uptake assay
The T cell stimulatory capacity of DCs derived from hES
cells CD34+ progenitor cells was assessed by co-incubat-
ing graded numbers of CD1a+ cells previously sorted on
the basis of CD1a immunomagnetic labeling (Miltenyi
Biotech, Auburn, CA), and irradiated (3500 rads) DCs for
5 days with 5 × 105 allogeneic peripheral T cells isolated
from peripheral blood using a column purification
method to isolate resting T cells per manufacturer's
instruction (Cedarlane, Ontario, CA). BrdU (10 µM final
concentration) was added 18 hr before harvest and incor-
poration was measured by permeabilizing the cells with
ice cold 70% ethanol for 20 min followed by washing in
PBS. The cells were resuspended in freshly prepared 2 N
HCl and incubated for 20 min at room temperature to
denature nuclear DNA. The cells were then neutralized
with 0.2 M disodiumborate and washed with PBS twice.
Cells were stained for 20 min with anti-BrdU antibody
conjugated with PE (BD-Pharmingen, San Jose, CA). Cells
were washed with PBS and analyzed by FACS to deter-
mine the percent incorporation of BrdU which is indica-
tive of proliferation. The percent BrdU was determined as
a function of input number of sorted DCs and plotted as
percent BrdU staining vs. input numbers of DCs. Alexa-
dextran was used to assess cell endocytosis as previously
described [25]. The antigen uptake capacity was deter-
mined using CD1a+ immunomagnetic purified hES-DCs
and FL-DCs. Cells resuspended in 10% FBS Iscove's
medium (~1 × 105 cells) were incubated with 1 mg/ml
Alexa-dextran at 37°C and 0°C for 60 minutes. The cells
were later washed with PBS five times prior to FACS anal-
ysis. The level of antigen uptake by DCs was expressed as
the difference in percentages between the test (37°C) and
control samples (0°C). Fetal liver derived CD34+ cells
were also evaluated in parallel.
HIV-1 infection of hES cells derived dendritic cells
To determine if hES-DCs can be infected with HIV-1 and
support viral replication, cells were incubated with a X4
tropic replication competent HIV-GFP reporter virus
NLENG-IRES [10,26]. An m.o.i of 0.2 in the presence of 4
µg/ml polybrene was used. Infected cells were visualized
by fluorescence microscopy to identify GFP expressing
cells. Infected culture supernatants were also assayed for
p24 antigen by ELISA using a Coulter-p24 kit (Beckman
Coulter, Fullerton, CA).
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